AC 430

Drug Profile

AC 430

Alternative Names: AC410/AC409; AC430

Latest Information Update: 24 Dec 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ambit Biosciences Corporation
  • Class Anti-inflammatories; Antineoplastics; Small molecules
  • Mechanism of Action Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Inflammation; Leukaemia

Most Recent Events

  • 24 Dec 2013 Discontinued - Phase-I for Leukaemia in USA (PO)
  • 24 Dec 2013 Discontinued - Preclinical for Autoimmune disorders in USA (PO)
  • 24 Dec 2013 Discontinued - Preclinical for Inflammation in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top